U.S. markets open in 7 hours 57 minutes
  • S&P Futures

    4,240.25
    +8.75 (+0.21%)
     
  • Dow Futures

    33,835.00
    +76.00 (+0.23%)
     
  • Nasdaq Futures

    14,299.00
    +36.00 (+0.25%)
     
  • Russell 2000 Futures

    2,307.20
    +6.90 (+0.30%)
     
  • Crude Oil

    73.20
    +0.12 (+0.16%)
     
  • Gold

    1,775.10
    -8.30 (-0.47%)
     
  • Silver

    25.92
    -0.19 (-0.73%)
     
  • EUR/USD

    1.1927
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    16.32
    -0.34 (-2.04%)
     
  • GBP/USD

    1.3955
    -0.0008 (-0.06%)
     
  • USD/JPY

    110.8380
    -0.1240 (-0.11%)
     
  • BTC-USD

    32,740.43
    -1,208.75 (-3.56%)
     
  • CMC Crypto 200

    791.40
    -18.80 (-2.32%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,869.42
    -5.47 (-0.02%)
     

Bearish: Analysts Just Cut Their Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenue and EPS estimates

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Today is shaping up negative for Seres Therapeutics, Inc. (NASDAQ:MCRB) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.

Following the downgrade, the consensus from eight analysts covering Seres Therapeutics is for revenues of US$20m in 2021, implying a painful 36% decline in sales compared to the last 12 months. Per-share losses are expected to explode, reaching US$1.64 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$25m and losses of US$1.42 per share in 2021. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

See our latest analysis for Seres Therapeutics

earnings-and-revenue-growth
earnings-and-revenue-growth

There was no major change to the consensus price target of US$38.00, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Seres Therapeutics, with the most bullish analyst valuing it at US$47.00 and the most bearish at US$24.00 per share. This is a fairly broad spread of estimates, suggesting that the analysts are forecasting a wide range of possible outcomes for the business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Seres Therapeutics' past performance and to peers in the same industry. We would highlight that sales are expected to reverse, with a forecast 45% annualised revenue decline to the end of 2021. That is a notable change from historical growth of 15% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 14% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Seres Therapeutics is expected to lag the wider industry.

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Seres Therapeutics. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Seres Therapeutics' revenues are expected to grow slower than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Seres Therapeutics after the downgrade.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Seres Therapeutics analysts - going out to 2025, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.